Stock Events

hVIVO. 

$0.35
89
+$0+0% Monday 20:00

Statistics

Day High
0.35
Day Low
0.35
52W High
0.35
52W Low
0.15
Volume
1,000
Avg. Volume
0
Mkt Cap
238.13M
P/E Ratio
0
Dividend Yield
0.71%
Dividend
0

Upcoming

Dividends

0.71%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

25SepConfirmed
Q2 2018
Q1 2019
Q2 2019
Q1 2023
Q2 2023
Q1 2024
Next
-0.16
0.12
0.4
0.68
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OPORF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical company that competes with hVIVO in the development of vaccines and therapeutics, including those for respiratory diseases.
Merck &
MRK
Mkt Cap318.55B
Merck is a leading healthcare company that develops vaccines and therapeutic drugs, competing with hVIVO in areas such as infectious disease treatment.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline is a pharmaceutical and biotechnology company that competes with hVIVO in the development of vaccines and treatments for various diseases, including respiratory infections.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is a global healthcare company that competes with hVIVO in the research and development of vaccines and treatments for infectious diseases.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson is a diversified healthcare company that competes with hVIVO in the development of drugs and vaccines, including those for infectious and respiratory diseases.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company that competes with hVIVO in the development of vaccines and treatments for various diseases, including COVID-19.
Novavax
NVAX
Mkt Cap1.94B
Novavax is a biotechnology company that focuses on the development of vaccines, directly competing with hVIVO in the vaccine development space, particularly for respiratory diseases.
BioNTech
BNTX
Mkt Cap20.32B
BioNTech is a biotechnology company that competes with hVIVO in the development of mRNA vaccines for infectious diseases, including COVID-19.
Moderna
MRNA
Mkt Cap46.43B
Moderna is a biotechnology company that specializes in mRNA technology for vaccines, competing with hVIVO in the development of vaccines for infectious diseases.
VBI Vaccines
VBIV
Mkt Cap17.06M
VBI Vaccines is a biopharmaceutical company that competes with hVIVO in the development of vaccines for infectious diseases, including hepatitis B and COVID-19.

About

Commercial Services
Miscellaneous Commercial Services
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
Show more...
CEO
Employees
274
Country
GB
ISIN
GB00B9275X97
WKN
000A1KAME

Listings